港股创新药再度走低，机构怎么看？520880跌逾2%下穿10日线，低吸资金躁动！

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a downturn, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping over 2% and falling below the 10-day moving average, indicating potential buying opportunities for investors [1][3]. Group 1: Market Performance - Major stocks in the innovative drug sector, such as Kangfang Biotech, fell by 4.5%, while others like 3SBio, China Biologic Products, and CSPC Pharmaceutical also declined [3]. - BeiGene's stock initially rose by 5.5% but later retreated along with the broader market [3]. - The innovative drug index has corrected approximately 20% from its peak, with some companies experiencing declines of 30% to 50%, shifting market sentiment from overly optimistic to a more pessimistic outlook [4]. Group 2: Investment Opportunities - Despite recent downturns, there is a rationale for renewed optimism in the innovative drug sector, as Chinese companies are reshaping the global innovative drug research ecosystem [4]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) is highlighted as a preferred investment tool, with its index comprising purely innovative drug companies and a significant concentration in leading firms [4]. - The top ten stocks in the ETF account for over 71% of its weight, showcasing the dominance of leading companies in the sector [5]. Group 3: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) has a total market value of 2.12 billion HKD and an average daily trading volume of 466 million HKD since its inception, making it the largest and most liquid ETF tracking the same index [5]. - The ETF's index, the Hang Seng Stock Connect Innovative Drug Select Index, is designed to exclude CXO companies, focusing solely on innovative drug development firms [4].